PlainPharmaWatch

CMS Open Payments · Program Year 2024

Merakris Therapeutics, Inc.

Merakris Therapeutics, Inc. reported $51,784.50 in payments to 9 physicians and teaching hospitals across 11 transactions.

See the rankings → How this is sourced
$51.8K
Total payments
11
Transactions
9
Recipients
+$10.0K
General Payments vs PY2023

Merakris Therapeutics, Inc. reported $51,784.50 in payments to 9 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #1341 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $5.8K per recipient across 2 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Merakris Therapeutics, Inc. pairs below-median payment volume with a moderately concentrated payment pattern.

#1341
of 1,925 companies
0.0%
of all US industry payments
0.5%
paid to its single top recipient
2
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Merakris Therapeutics, Inc.'s CMS-reported General Payments increased by $10.0K (+2516.8%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2023: MERAKRIS THERAPEUTICS, INC.PY2024: Merakris Therapeutics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$396.00PY2024$10.4K
PY2023
$396.00
PY2024
$10,362.50

How Merakris Therapeutics, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Merakris Therapeutics, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$51,785 30th percentile higher than 30% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). This entry sits in this band. $78,003–$242,294: 295 reporting companies (15%). Above this entry. $242,294–$752,621: 270 reporting companies (14%). Above this entry. $752,621–$2,337,813: 263 reporting companies (14%). Above this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Merakris Therapeutics, Inc.

In Program Year 2024, Merakris Therapeutics, Inc. reported $51,784.50 in payments to 9 physicians and teaching hospitals across 11 individual transactions, an average of $4.7K per transaction and $5.8K per recipient. That total places Merakris Therapeutics, Inc. at rank #1341 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $5.3K, accounting for 10.2% of the company's reported total and 4 transactions.

General Payment Breakdown by Type

Merakris Therapeutics, Inc. made 2 types of general payments. "Consulting Fee" is the largest category at $5.3K, 10.2% of the company's reported total.

How Merakris Therapeutics, Inc. divides its payments

How the reported total splits across payment categories

1. Consulting Fee$5.3K2. Compensation for Services…$5.1K
Payment Type Amount Transactions
Consulting Fee $5.3K 4
Compensation for Services Other Than Consulting $5.1K 5

Recipient Concentration in General Payments

The five largest recipient relationships account for $10,237.50 (98.8%) of $10,362.50 in this company's General Payments records across 6 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Merakris Therapeutics, Inc.

The five named recipients with the highest reported General Payments from this company

Sharon Yvonne Hook$5.3KSarah Ducharme$3.0KJengyu Lai$1.5KLinda Rose$250.00Jeffrey Richard Varanelli$187.50
  1. 1

    Sharon Yvonne Hook

    $5,300.00 across 4 reported transactions

  2. 2

    Sarah Ducharme

    $3,000.00 across 1 reported transactions

  3. 3

    Jengyu Lai

    $1,500.00 across 1 reported transactions

  4. 4

    Linda Rose

    $250.00 across 1 reported transactions

  5. 5

    Jeffrey Richard Varanelli

    $187.50 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $4.7K. Average per recipient: $5.8K.

Total Amount

$51,784.50

Avg per Transaction

$4.7K

Avg per Recipient

$5.8K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Merakris Therapeutics, Inc. Share

0.0%

#1341 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Merakris Therapeutics, Inc.

Vaporox, Inc.

$51.8K 102 recipients

United Imaging Healthcare North America LLC

$51.7K 170 recipients

Infinity BiologiX LLC

$52.4K 9 recipients

Steelhead Surgical Inc

$51.2K 378 recipients

Roche Diabetes Care GmbH

$52.4K 31 recipients

Seagen Inc.

$52.4K 561 recipients

Frequently Asked Questions

How much did Merakris Therapeutics, Inc. pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $51,784.50 from Merakris Therapeutics, Inc. to physicians and hospitals across 11 transactions - 0.0% of all industry payments reported that year.
How many physicians received payments from Merakris Therapeutics, Inc.? ▾
9 physicians and teaching hospitals received payments from Merakris Therapeutics, Inc. in 2024, averaging $5.8K per recipient.
What types of payments did Merakris Therapeutics, Inc. make? ▾
2 categories of general payment make up Merakris Therapeutics, Inc.'s reported activity, including consulting, meals, travel, and similar types. The largest general-payment category was "Consulting Fee" at $5.3K, representing 10.2% of the company's reported total.
How does Merakris Therapeutics, Inc. rank among pharmaceutical companies? ▾
Out of 1,925 companies in the CMS Open Payments database for 2024, Merakris Therapeutics, Inc. ranks #1341 by total payment amount.
What is the average payment size from Merakris Therapeutics, Inc.? ▾
In 2024, Merakris Therapeutics, Inc. averaged $4.7K per transaction across 11 transactions to 9 recipients.
Where does the payment data for Merakris Therapeutics, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Merakris Therapeutics, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.